Physician profile
Aaron Templeton
NPI 1689974420
$4,542.30
in general payments reported to CMS, 2019-2025
33 companies · $2,055 in 2025
The $2,055 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $207 · 2023: $797 · 2024: $1,205 · 2025: $2,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,056.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,270.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $406.27 | 2021-2025 | |
| Abbvie INC. | $343.80 | 2023-2025 | |
| Lilly USA, LLC | $289.62 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $241.75 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $228.92 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $210.70 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $174.01 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $148.75 | 2023-2025 | Otezla, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.41 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $122.43 | 2022-2023 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $90.83 | 2024-2025 | Voquezna |
| Dynavax Technologies Corporation | $90.06 | 2023-2025 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $82.07 | 2023-2025 | Xarelto, Spravato |
| Otsuka America Pharmaceutical, INC. | $71.83 | 2024-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $71.11 | 2025 | |
| Dexcom, INC. | $66.01 | 2023-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $57.21 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $54.95 | 2024-2025 | Auvelity |
| Daiichi Sankyo INC. | $49.16 | 2021-2024 | Injectafer |
| Shield Therapeutics INC | $41.57 | 2023 | Accrufer |
| Antares Pharma, INC. | $40.97 | 2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.88 | 2024 | Jardiance, Tradjenta, Synjardy |
| Genzyme Corporation | $29.97 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $29.29 | 2025 | Austedo Xr |
| Inspire Medical Systems, INC. | $26.14 | 2024 | Inspire |
| Hologic Sales and Service, LLC | $25.78 | 2025 | Aptima |
| Lucid Diagnostics INC. | $20.17 | 2023 | |
| Merck Sharp & Dohme LLC | $18.88 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Esperion Therapeutics, INC. | $17.18 | 2021 | |
| Sumitomo Pharma America, INC. | $15.68 | 2023 | Gemtesa |
| Nevro Corp. | $14.71 | 2023 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Templeton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.